SG171593A1 - Inhibitors of c-fms kinase - Google Patents

Inhibitors of c-fms kinase

Info

Publication number
SG171593A1
SG171593A1 SG201102830-5A SG2011028305A SG171593A1 SG 171593 A1 SG171593 A1 SG 171593A1 SG 2011028305 A SG2011028305 A SG 2011028305A SG 171593 A1 SG171593 A1 SG 171593A1
Authority
SG
Singapore
Prior art keywords
inhibitors
fms kinase
fms
kinase
compounds
Prior art date
Application number
SG201102830-5A
Other languages
English (en)
Inventor
Carl R Illig
Shelley K Ballentine
Jinsheng Chen
Renee Louise Desjarlais
Sanath K Meegalla
Bruce E Tomczuk
Mark Wall
Kenneth Wilson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG171593A1 publication Critical patent/SG171593A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
SG201102830-5A 2006-04-20 2007-04-18 Inhibitors of c-fms kinase SG171593A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79366706P 2006-04-20 2006-04-20

Publications (1)

Publication Number Publication Date
SG171593A1 true SG171593A1 (en) 2011-06-29

Family

ID=38472852

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201102830-5A SG171593A1 (en) 2006-04-20 2007-04-18 Inhibitors of c-fms kinase

Country Status (23)

Country Link
US (7) US8815867B2 (pt)
EP (3) EP2016070B1 (pt)
JP (3) JP5331680B2 (pt)
KR (3) KR101367646B1 (pt)
CN (1) CN101472914B (pt)
AR (3) AR060611A1 (pt)
AU (3) AU2007240443B2 (pt)
BR (1) BRPI0710548B8 (pt)
CA (3) CA2649924C (pt)
ES (3) ES2565238T3 (pt)
HK (1) HK1133878A1 (pt)
IL (1) IL194845A (pt)
MX (3) MX2008013529A (pt)
NO (1) NO20084896L (pt)
NZ (3) NZ572070A (pt)
PE (1) PE20080074A1 (pt)
RU (1) RU2475483C2 (pt)
SG (1) SG171593A1 (pt)
TW (3) TW200806659A (pt)
UA (1) UA93085C2 (pt)
UY (1) UY30297A1 (pt)
WO (3) WO2007124322A1 (pt)
ZA (1) ZA200809873B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
EP1984024A2 (en) * 2006-01-05 2008-10-29 Novartis AG Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2021329B1 (en) * 2006-04-20 2016-04-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
MX2008013533A (es) 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.
CA2649924C (en) 2006-04-20 2014-08-19 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
EP2015748B1 (en) * 2006-04-20 2012-07-04 Janssen Pharmaceutica NV A C-Kit kinase inhibitor for use in the treatment of gastrointestinal stromal tumor or mastocytosis
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
EP2521782B1 (en) 2010-01-05 2019-04-10 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3 receptor antagonists for the treatment or the prevention of pain disorders
US10106798B2 (en) 2010-01-05 2018-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
HUE032754T2 (en) 2011-05-05 2017-10-30 Novartis Ag CSF-1R inhibitors for the treatment of brain tumors
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013299922B2 (en) 2012-08-07 2018-06-21 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3052485B1 (en) 2013-10-04 2021-07-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX371017B (es) * 2014-02-03 2020-01-13 Vitae Pharmaceuticals Llc Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma.
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2021144360A1 (en) 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Small molecule csf-1r inhibitors in therapeutic and cosmetic uses
CN112441941B (zh) * 2020-12-03 2022-08-02 浙江荣耀生物科技股份有限公司 一种1-(4-氨基苯基)环戊基甲腈的制备方法

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2466420A (en) 1947-11-26 1949-04-05 Eastman Kodak Co Ketene condensation products with aldehydes
US3226394A (en) 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
CH504416A (de) 1966-12-05 1971-03-15 Ciba Geigy Ag Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen
US4551540A (en) 1983-01-17 1985-11-05 Borg-Warner Chemicals, Inc. Substituted 2,5-dimethylpyrroles
JPH0264704A (ja) 1988-08-30 1990-03-05 Honda Motor Co Ltd 自動化設備の制御システム
DE68926702T2 (de) * 1988-09-08 1996-12-19 Sony Corp Bildverarbeitungsgerät
JPH0299250A (ja) 1988-09-30 1990-04-11 Kobe Steel Ltd タンディッシュのスラグ除去方法
JP2833106B2 (ja) 1990-02-21 1998-12-09 株式会社島津製作所 液体クロマトグラフ
JPH03255915A (ja) 1990-03-07 1991-11-14 Nkk Corp 流量検出装置
US5190541A (en) 1990-10-17 1993-03-02 Boston Scientific Corporation Surgical instrument and method
JPH04184937A (ja) 1990-11-20 1992-07-01 Oki Electric Ind Co Ltd 半導体集積回路装置の製造方法
JPH04212503A (ja) 1990-12-05 1992-08-04 Mitsubishi Electric Corp トリプレート線路共振器
JPH0821207B2 (ja) 1992-02-03 1996-03-04 日本コロムビア株式会社 ディスク装置
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
JPH05293265A (ja) 1992-04-17 1993-11-09 Juki Corp 千鳥縫いミシンの針振り駆動変更装置
JPH0815587B2 (ja) 1992-05-01 1996-02-21 東亜工業株式会社 振動ふるい
JPH05346639A (ja) 1992-06-15 1993-12-27 Konica Corp 写真処理廃液の再利用方法
JPH0684710A (ja) 1992-09-03 1994-03-25 Matsushita Electric Ind Co Ltd 電解コンデンサ
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
KR100360206B1 (ko) * 1992-12-10 2003-02-11 소니 가부시끼 가이샤 화상신호변환장치
JP3243861B2 (ja) 1992-12-10 2002-01-07 ソニー株式会社 画像情報変換装置
JPH06189231A (ja) * 1992-12-16 1994-07-08 Toshiba Corp 液晶表示装置
JP3522818B2 (ja) 1993-02-26 2004-04-26 富士写真フイルム株式会社 写真用支持体
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
JP3192537B2 (ja) 1993-11-18 2001-07-30 キヤノン株式会社 走査光学装置
JP3197737B2 (ja) 1994-02-15 2001-08-13 三洋電機株式会社 コインメカニズムの取付け装置
JPH07310319A (ja) 1994-05-19 1995-11-28 Katsuyuki Hasegawa 杭打ち装置及び杭打ちアタッチメント
JP3592748B2 (ja) 1994-07-01 2004-11-24 三菱重工業株式会社 蒸気、ガスタービン複合プラントの廃熱による蒸気生成システム
JPH08107715A (ja) 1994-10-13 1996-04-30 Iseki & Co Ltd コンバインの拡縮式グレンタンク装置
WO1996011932A1 (en) 1994-10-14 1996-04-25 Smithkline Beecham Plc 2-(imidazol-4-yl)carbapeneme derivatives, intermediates thereof and use as antibacterials
JP3357754B2 (ja) 1994-10-18 2002-12-16 三洋電機株式会社 疑似ステレオ画像生成方法及び疑似ステレオ画像生成装置
JPH08287118A (ja) 1995-02-16 1996-11-01 Fujitsu Ltd 部品標準化方式
JPH07322944A (ja) 1995-04-10 1995-12-12 Sanyo Electric Co Ltd 透視板
EP0822788B1 (en) 1995-04-19 2002-09-04 Schneider (Usa) Inc. Drug release coated stent
US6117432A (en) 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
JP3415333B2 (ja) 1995-07-13 2003-06-09 トヨタ自動車株式会社 水素吸蔵合金
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IL123568A (en) 1995-12-08 2001-08-08 Janssen Pharmaceutica Nv History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5702390A (en) 1996-03-12 1997-12-30 Ethicon Endo-Surgery, Inc. Bioplar cutting and coagulation instrument
WO1998006700A1 (en) 1996-08-09 1998-02-19 Merck & Co., Inc. Stereoselective deoxygenation reaction
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
ATE252104T1 (de) 1996-12-20 2003-11-15 Tovarischestvo S Ogranichennoi Verfahren und gerät zur herstellung von 1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12- lid- hydrochlorid
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
IL130363A (en) 1997-04-25 2002-08-14 Janssen Pharmaceutica Nv Quinazolines that inhibit frenzyl transferase, their preparation and pharmaceutical preparations containing them
TW491872B (en) 1997-05-27 2002-06-21 Ciba Sc Holding Ag Block oligomers containing l-hydrocarbyloxy-2,2,6,6-tetramethyl-4- piperidyl groups as stabilizers for lower polyolefin
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
JP4022044B2 (ja) 1998-03-05 2007-12-12 フォーミュラ ワン アドミニストレイション リミテッド データ通信システム
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
AU5086499A (en) 1998-07-01 2000-01-24 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
JP2002520324A (ja) 1998-07-10 2002-07-09 メルク エンド カムパニー インコーポレーテッド 新規な血管形成インヒビター
US6284098B1 (en) * 1998-07-20 2001-09-04 Wwj, Llc Lignocellulose fiber filler for thermoplastic composite compositions
ATE321037T1 (de) 1998-08-27 2006-04-15 Pfizer Prod Inc Als antikrebsmittel verwendbare alkinyl- substituierte chinolin-2-on-derivate
EP1107962B1 (en) 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
KR100712226B1 (ko) 1998-12-23 2007-04-27 얀센 파마슈티카 엔.브이. 1,2-어닐링된 퀴놀린 유도체
WO2000042042A2 (en) 1999-01-11 2000-07-20 Princeton University High affinity inhibitors for target validation and uses thereof
ES2391550T3 (es) 1999-04-15 2012-11-27 Bristol-Myers Squibb Company Inhibidores cíclicos de la proteína tirosina quinasa
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP3766231B2 (ja) 1999-05-10 2006-04-12 Ｎｅｃビューテクノロジー株式会社 液晶表示装置
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
DE60040786D1 (de) * 1999-08-05 2008-12-24 Sanyo Electric Co Bildinterpolationsverfahren
JP2001078113A (ja) * 1999-09-06 2001-03-23 Sony Corp 映像機器および映像表示方法
US6852752B2 (en) 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CA2394727A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
FR2803592A1 (fr) 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US6558385B1 (en) 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
US6692491B1 (en) 2000-03-24 2004-02-17 Scimed Life Systems, Inc. Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
JP4150947B2 (ja) * 2000-08-23 2008-09-17 ソニー株式会社 画像処理装置および方法、並びに記録媒体
CA2424689A1 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
TWI302836B (en) 2001-10-30 2008-11-11 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003057690A1 (en) 2001-12-27 2003-07-17 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
JP4218249B2 (ja) * 2002-03-07 2009-02-04 株式会社日立製作所 表示装置
IL165264A0 (en) 2002-05-23 2005-12-18 Cytopia Pty Ltd Protein kinase inhibitors
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
AU2003258491A1 (en) 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
EP1549614A4 (en) 2002-10-03 2008-04-16 Targegen Inc VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
KR20050086736A (ko) 2002-11-18 2005-08-30 폴리머릭스 코포레이션 신규 중합체를 이용하는 의학용 장치
KR101159519B1 (ko) 2002-11-19 2012-06-25 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｒｒｅ 및 ｃｔｅ를 포함하는 유전자 작제물 및 조성물 및이의 용도
AU2003297160A1 (en) 2002-12-18 2004-07-22 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
CA2521830A1 (en) 2003-04-09 2004-10-21 Japan Tobacco Inc. Heteroaromatic pentacyclic compound and medicinal use thereof
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
US7790724B2 (en) 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
US20050113566A1 (en) 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
MXPA05011503A (es) 2003-04-25 2006-05-31 Johnson & Johnson Inhibidores de la c-fms cinasa.
WO2005012220A2 (en) 2003-07-28 2005-02-10 Smithkline Beecham Corporation Cycloalkylidene compounds as modulators of estrogen receptor
PL1684750T3 (pl) 2003-10-23 2010-10-29 Ab Science 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej
GB0326601D0 (en) 2003-11-14 2003-12-17 Novartis Ag Organic compounds
AU2005209485A1 (en) 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
JP4628770B2 (ja) * 2004-02-09 2011-02-09 株式会社日立製作所 照明装置を備えた画像表示装置及び画像表示方法
JP2006084710A (ja) * 2004-09-15 2006-03-30 Toshiba Matsushita Display Technology Co Ltd 表示制御回路、表示制御方法、および液晶表示装置
US20060132383A1 (en) 2004-09-27 2006-06-22 Idc, Llc System and method for illuminating interferometric modulator display
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
CN101437514B (zh) 2004-10-22 2012-04-25 詹森药业有限公司 C-fms激酶抑制剂
WO2006047504A1 (en) 2004-10-22 2006-05-04 Janssen Pharmaceutica, N.V. Aromatic amides as inhibitors of c-fms kinase
NZ555289A (en) 2004-10-22 2010-10-29 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
JP4904783B2 (ja) 2005-03-24 2012-03-28 ソニー株式会社 表示装置及び表示方法
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281769A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281771A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
BRPI0617489A2 (pt) 2005-10-18 2011-07-26 Janssen Pharmaceutica Nv compostos, composiÇço e uso de ditos compostos para inibir a flt3 cinase
NZ594383A (en) 2005-11-03 2013-05-31 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
AU2006315334B2 (en) 2005-11-16 2011-05-19 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP4950480B2 (ja) * 2005-11-22 2012-06-13 東芝モバイルディスプレイ株式会社 液晶表示装置
KR100815916B1 (ko) * 2006-02-09 2008-03-21 엘지.필립스 엘시디 주식회사 액정 표시장치의 구동장치 및 구동방법
CA2649924C (en) * 2006-04-20 2014-08-19 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
EP2021329B1 (en) 2006-04-20 2016-04-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
MX2008013533A (es) 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
JP2008096956A (ja) * 2006-09-15 2008-04-24 Olympus Corp 画像表示方法および画像表示装置
JP4479709B2 (ja) * 2006-10-27 2010-06-09 セイコーエプソン株式会社 画像表示装置、画像表示方法、画像表示プログラム、及び画像表示プログラムを記録した記録媒体、並びに電子機器
TWI354960B (en) * 2006-11-07 2011-12-21 Realtek Semiconductor Corp Method for controlling display device
JP4285532B2 (ja) 2006-12-01 2009-06-24 ソニー株式会社 バックライト制御装置、バックライト制御方法、および液晶表示装置
JP5117762B2 (ja) * 2007-05-18 2013-01-16 株式会社半導体エネルギー研究所 液晶表示装置
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US20090148883A1 (en) 2007-10-31 2009-06-11 Manthey Carl L Biomarker for assessing response to fms treatment
JP4806102B2 (ja) 2008-06-27 2011-11-02 シャープ株式会社 液晶表示装置の制御装置、液晶表示装置、液晶表示装置の制御方法、プログラムおよび記録媒体

Also Published As

Publication number Publication date
AR060612A1 (es) 2008-07-02
UA93085C2 (en) 2011-01-10
TW200806659A (en) 2008-02-01
PE20080074A1 (es) 2008-02-11
EP2016070B1 (en) 2016-01-13
ES2566772T3 (es) 2016-04-15
TW200815414A (en) 2008-04-01
AR060611A1 (es) 2008-07-02
NZ572070A (en) 2011-09-30
CA2650057A1 (en) 2007-11-01
US20070249685A1 (en) 2007-10-25
CN101472914A (zh) 2009-07-01
RU2475483C2 (ru) 2013-02-20
US9394289B2 (en) 2016-07-19
CA2649739A1 (en) 2007-11-01
AU2007240440A1 (en) 2007-11-01
US20140200245A1 (en) 2014-07-17
US9266866B2 (en) 2016-02-23
ZA200809873B (en) 2010-02-24
CA2649739C (en) 2015-09-01
KR101367646B1 (ko) 2014-02-27
BRPI0710548A2 (pt) 2012-06-05
US20140329815A1 (en) 2014-11-06
EP2016058B1 (en) 2016-01-06
KR20090003343A (ko) 2009-01-09
WO2007124322A1 (en) 2007-11-01
NZ572072A (en) 2011-09-30
CA2649924A1 (en) 2007-11-01
TWI411612B (zh) 2013-10-11
AU2007240443B2 (en) 2012-11-01
BRPI0710548B8 (pt) 2021-05-25
WO2007124319A1 (en) 2007-11-01
KR20080110917A (ko) 2008-12-19
AR060610A1 (es) 2008-07-02
ES2564781T3 (es) 2016-03-29
JP2009534406A (ja) 2009-09-24
US20070249608A1 (en) 2007-10-25
JP2009534407A (ja) 2009-09-24
US8859602B2 (en) 2014-10-14
US8722718B2 (en) 2014-05-13
ES2565238T3 (es) 2016-04-01
US20070249680A1 (en) 2007-10-25
US20160122334A1 (en) 2016-05-05
EP2016074A1 (en) 2009-01-21
JP5331679B2 (ja) 2013-10-30
IL194845A0 (en) 2009-08-03
AU2007240442A1 (en) 2007-11-01
UY30297A1 (es) 2007-08-31
US9403804B2 (en) 2016-08-02
EP2016074B1 (en) 2016-01-13
RU2008145763A (ru) 2010-05-27
NZ572071A (en) 2011-12-22
NO20084896L (no) 2009-01-12
TW200815415A (en) 2008-04-01
JP2009534405A (ja) 2009-09-24
KR101491564B1 (ko) 2015-02-09
CN101472914B (zh) 2015-05-20
AU2007240440B2 (en) 2012-09-20
JP5331680B2 (ja) 2013-10-30
EP2016070A1 (en) 2009-01-21
WO2007124321A1 (en) 2007-11-01
CA2649924C (en) 2014-08-19
US8815867B2 (en) 2014-08-26
US20140378457A1 (en) 2014-12-25
EP2016058A1 (en) 2009-01-21
MX2008013531A (es) 2009-01-20
KR20090015066A (ko) 2009-02-11
KR101406877B1 (ko) 2014-06-13
HK1133878A1 (en) 2010-04-09
AU2007240443A1 (en) 2007-11-01
JP5331681B2 (ja) 2013-10-30
IL194845A (en) 2014-11-30
BRPI0710548B1 (pt) 2020-03-24
MX2008013529A (es) 2009-01-15
MX2008013530A (es) 2009-01-14
AU2007240442B2 (en) 2012-09-06
CA2650057C (en) 2014-07-29

Similar Documents

Publication Publication Date Title
SG171593A1 (en) Inhibitors of c-fms kinase
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
PL2021335T3 (pl) Związki heterocykliczne jako inhibitory kinazy C-FMS
WO2007105058A3 (en) Pyrazole compounds
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
PL1761520T3 (pl) Inhibitory kinazy
SG171617A1 (en) Therapeutic compounds
JO2947B1 (en) Compounds corresponding to cyclopamine
AU2009313134A8 (en) Novel halogen-substituted compounds
MD20140047A2 (ro) Inhibitori ai protein kinazei
PL2250172T3 (pl) Pirolopirazynowe inhibitory kinazy
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
MY150596A (en) Hsp90 inhibitors
MY150542A (en) Cmet inhibitors
TN2010000131A1 (en) Polo-like kinase inhibitors
EA200900945A1 (ru) Новый способ синтеза агомелатина
MX2009005934A (es) Compuestos organicos.
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
EA200900946A1 (ru) Новый способ синтеза агомелатина
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
MX2009004947A (es) Arilsulfonil-pirrolidinas como inhibidores 5-hidroxitriptaminas6 (5-ht6).
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина